SEC Company Response from Tango Therapeutics, Inc. (TNGX) (CIK 0001819133) (TNGX) — Sep 8, 2022
Tango Therapeutics, Inc. (TNGX) (CIK 0001819133)
Date: Sept. 8, 2022 · CIK: 0001819133 · Accession: 0001193125-22-240987
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267224
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jordan Nimitz Re: Tango Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-267224
Dear Ms. Nimitz,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tango Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 12, 2022, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling William Collins at (617) 570-1447.
If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447.
Sincerely,
TANGO THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR September 8, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jordan Nimitz Re: Tango Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-267224 Dear Ms. Nimitz, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tango Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 12, 2022, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling William Collins at (617) 570-1447. If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447. Sincerely, TANGO THERAPEUTICS, INC. /s/ Barbara Weber Barbara Weber Chief Executive Officer and President cc: Daniella Beckman, Tango Therapeutics, Inc. Douglas Barry, Tango Therapeutics, Inc. William Collins, Esq., Goodwin Procter LLP